Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer.
Kunpeng XuJun LiangTao ZhangZongmei ZhouDongfu ChenQin-Fu FengZefen XiaoZhouguang HuiJima LuXin WangLei DengWenyang LiuJianyang WangYirui ZhaiJie WangNan BiLuhua WangPublished in: Thoracic cancer (2021)
The combination of EGFR-TKI and radiotherapy might carry a risk of pneumonitis; however, there are limited data concerning dose constraints. Our results showed a slightly higher incidence of mild or moderate radiation pneumonitis by strict dose limitation.
Keyphrases
- locally advanced
- tyrosine kinase
- small cell lung cancer
- epidermal growth factor receptor
- radiation induced
- rectal cancer
- interstitial lung disease
- early stage
- radiation therapy
- squamous cell carcinoma
- advanced non small cell lung cancer
- systemic sclerosis
- chronic myeloid leukemia
- electronic health record
- risk factors
- high intensity
- big data
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- artificial intelligence